About us

One of the most serious safety problems within hemodialysis remains to quickly detect venous needle dislodgement (VND) and catheter leakage.

To improve patient safety, Redsense Medical has developed a monitoring system that can detect the very first sign of a blood leak using patented fiber optic technology. An alarm is triggered when the sensor comes into contact with blood so one can address the issue immediately and stop the blood flow.

Redsense cares about your safety, Feel safe, be safe

The Redsense alarm unit features easy one-button operation and options to monitor venous needle or catheter access. From the very start, development of the company’s technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector. The system is the only blood leakage system on the market that is both CE marked and FDA cleared for sales in the USA.

Let Redsense keep an eye on your access.

In more than 15 years of clinical use, patients and nurses have felt safer when using the Redsense alarm system to detect VND. Redsense is proud to count the 5 largest dialysis providers in the USA, and 3 in the top 5 best nephrology hospitals in the USA – Mayo Clinic, New York Presbyterian, Cleveland Clinics – among users of the Redsense blood leakage system.

The US department of Veteran Affairs even mandates the use of Redsense.

Cleveland Clinics case study

Cleveland Clinic provides both inpatient and outpatient hemodialysis for high-acuity patients with a higher than average risk for Venous Needle Dislodgement (VND). In February 2010 a quality improvement project was introduced to reduce VND rates. In the prior 3 months, internal data review showed 3 undetected VND episodes (2 class IV hemorrhages), incidence of 1 VND per 538 HD treatments.

The project introduced Redsense blood detection device alongside the standard policies and procedures for cleaning, disinfecting, and securing the venous access wound and the venous needles. Zero undetected VND episodes were recorded between February 15 and December 30 2010. The overall occurrence dropped from 13 in 2009 to 4 in 2010, incidence of 1 VND per 1750 HD treatments. Redsense helped in achieving a relative risk reduction of 70% in the Cleveland Clinic.